Develops oncology therapeutics, focusing on cancer therapy and treatment-resistant tumors.
BioLineRx Ltd., a leading clinical-stage biopharmaceutical development company headquartered in Hevel Modi'in, Israel, specializes in pioneering treatments primarily within the field of oncology.
At the heart of BioLineRx's innovative pipeline is Motixafortide, a peptide with multiple ongoing clinical trials. Motixafortide has completed Phase 3 trials for autologous stem cell mobilization and Phase 2a trials for pancreatic cancer. The peptide is currently being evaluated in Phase 2 trials for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for solid tumors and acute myeloid leukemia. Additionally, BioLineRx is advancing AGI-134, an immuno-oncology agent in Phase 1/2a trials for solid tumors, and BL-5010, a proprietary pen-like applicator designed for non-surgical removal of skin lesions.
BioLineRx has established strategic collaborations to enhance its development efforts. Collaborations include a partnership with MSD focusing on cancer immunotherapy, joint research with MD Anderson Cancer Center to investigate Motixafortide combined with KEYTRUDA (pembrolizumab) in pancreatic cancer, and a licensing arrangement with Perrigo Company plc for the over-the-counter sale of BL-5010.
Founded in 2003, BioLineRx continues to drive innovation in biopharmaceuticals, leveraging its expertise and strategic partnerships to advance novel therapies that address critical unmet needs in oncology and beyond.